Mitsubishi UFJ Securities Holdings Co. Ltd. acquired a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) in the first quarter, HoldingsChannel reports. The firm acquired 650 shares of the medical research company’s stock, valued at approximately $94,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Blackcrane Capital LLC grew its stake in Iqvia by 28.1% during the first quarter. Blackcrane Capital LLC now owns 51,005 shares of the medical research company’s stock worth $7,337,000 after buying an additional 11,183 shares during the last quarter. GYL Financial Synergies LLC bought a new stake in Iqvia during the first quarter worth about $4,349,000. Riverhead Capital Management LLC grew its stake in Iqvia by 19.2% during the first quarter. Riverhead Capital Management LLC now owns 7,521 shares of the medical research company’s stock worth $1,082,000 after buying an additional 1,211 shares during the last quarter. Northeast Financial Consultants Inc bought a new stake in Iqvia during the first quarter worth about $642,000. Finally, Andra AP fonden bought a new stake in Iqvia during the first quarter worth about $7,380,000. 89.78% of the stock is owned by institutional investors and hedge funds.
In related news, insider Kevin C. Knightly sold 46,080 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $138.06, for a total value of $6,361,804.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael J. Evanisko sold 1,193 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. Insiders sold 143,273 shares of company stock worth $20,066,890 over the last 90 days. 6.00% of the stock is currently owned by company insiders.
Several analysts have weighed in on IQV shares. UBS Group set a $170.00 price objective on shares of Iqvia and gave the stock a “buy” rating in a research note on Friday, February 15th. Barclays increased their price target on shares of Iqvia from $160.00 to $167.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Wells Fargo & Co increased their price target on shares of Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a research note on Tuesday, February 19th. Piper Jaffray Companies increased their price target on shares of Iqvia to $148.00 and gave the company a “neutral” rating in a research note on Friday, February 15th. Finally, Leerink Swann started coverage on shares of Iqvia in a research note on Tuesday, May 28th. They set an “outperform” rating and a $136.38 price target on the stock. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $147.02.
Shares of IQV traded up $0.08 during mid-day trading on Wednesday, hitting $139.51. 29,434 shares of the company traded hands, compared to its average volume of 1,250,267. Iqvia Holdings Inc has a one year low of $97.64 and a one year high of $146.10. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a market capitalization of $27.34 billion, a P/E ratio of 27.25, a price-to-earnings-growth ratio of 1.68 and a beta of 0.77.
Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.12. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The business had revenue of $2.68 billion for the quarter, compared to analysts’ expectations of $2.67 billion. During the same period in the prior year, the firm earned $1.34 earnings per share. Iqvia’s revenue was up 4.7% compared to the same quarter last year. As a group, analysts anticipate that Iqvia Holdings Inc will post 5.88 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Mitsubishi UFJ Securities Holdings Co. Ltd. Acquires New Stake in Iqvia Holdings Inc (NYSE:IQV)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2019/06/12/mitsubishi-ufj-securities-holdings-co-ltd-acquires-new-stake-in-iqvia-holdings-inc-nyseiqv.html.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Story: Day Trading – Risk Worth the Reward?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.